Publicaciones en colaboración con investigadores/as de Hospital Virgen de La Luz de Cuenca (63)

2024

  1. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: Results from the EU-GEI case-control study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7375-7384

  3. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  4. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  5. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  6. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  7. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  8. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  9. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  10. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 5, pp. 1970-1978

  11. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

    Psychological medicine, Vol. 53, Núm. 15, pp. 7418-7427

  12. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  13. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

2022

  1. A bacteraemia risk prediction model: development and validation in an emergency medicine population

    Infection, Vol. 50, Núm. 1, pp. 203-221

  2. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  3. Childhood Maltreatment, Educational Attainment, and IQ: Findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

    Schizophrenia Bulletin, Vol. 48, Núm. 3, pp. 575-589

  4. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

    Psychological Medicine, Vol. 52, Núm. 10, pp. 1910-1922

  5. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  6. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study

    Schizophrenia bulletin, Vol. 48, Núm. 5, pp. 1104-1114